1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

  • August 2016
  • -
  • GBI Research
  • -
  • 68 pages

Summary

Table of Contents

Search Inside

Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

Summary
Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibiting distinct underlying etiologies and patho-physiologies. While technological advances and extensive research efforts have furthered the understanding of the pathophysiology of these complex indications, substantial gaps in scientific knowledge remain.

Pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action. Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena.

The active pain pipeline is populated by 810 products across all stages of development, which exhibit a highly diverse range of molecular targets. It is identified that 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 first-in-class molecular targets.

Global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products’ efficacy in treating moderate to severe acute pain. Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, due to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.

The report “Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes” provides a brief analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape.

In depth, it provides the following -
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Helps to identify and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing.

Scope
- Analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing.
- A brief introduction to chronic and acute pain, including subtypes, symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for pain therapeutics, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy
- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the pain markets in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the pain pipeline, stratified by pain subtype, stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the pain deals landscape by analyzing trends in licensing and co-development deals, and producing a list of pain therapeutics that are not yet involved in deals and may be potential investment opportunities.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Opportunity in Analgesics in global market - 2017

Opportunity in Analgesics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...

Global OTC Analgesics Market - Growth, Trends and Forecast (2017 - 2022)

Global OTC Analgesics Market - Growth, Trends and Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The global OTC Analgesics market accounted for a market value of USD XX billion in 2015. The market is expected to reach USD XX billion in 2016 and USD XX billion by 2021, growing at a CAGR of xx% during ...

Pain and Fever Relief Drugs Markets in China

Pain and Fever Relief Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Pain and Fever Relief Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market and Digestive System Disorder Statistics in the US

  • April 2017
    20 pages
  • Opioid  

    Digestive Syste...  

  • United States  

View report >

Therapy Market and Targeted Therapy Market in the UK

  • April 2017
    77 pages
  • Therapy  

    Targeted Therap...  

    Digestive Syste...  

  • United Kingdom  

View report >

Opioid Market in the US

  • March 2017
    4 pages
  • Opioid  

  • United States  

    North America  

View report >

Related Market Segments :

Analgesic
Opioid
Therapy
Chronic Pain

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.